US · SBC · CONSULTING SERVICES
SBC Medical Group Holdings Incorporated (SBC) intrinsic value and stock valuation
$5.17as of 2026-11-21 · Mkt cap 313.68M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
SBC Medical Group Holdings Incorporated DCF and intrinsic value
InvestorsCraft values SBC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SBC’s statements →
SBC Medical Group Holdings Incorporated Graham Number
Graham Number: $5.34d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2022–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Wabash National Corporation (WNC) $9.93
- The Manitowoc Company, Inc. (MTW) $20.31
- Concrete Pumping Holdings, Inc. (BBCP) $9.10
- Pangaea Logistics Solutions, Ltd. (PANL) $7.91
- Luxfer Holdings PLC (LXFR) $17.35
- Spire Global, Inc. (SPIR) $7.36
- ACCO Brands Corporation (ACCO) $5.39
- KNOT Offshore Partners LP (KNOP) $7.32
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $173.6M | $205.4M | $193.5M | $174.2M |
| Operating income | $67.5M | $70.3M | $70.7M | $20.1M |
| Net income | $51M | $46.6M | $39.4M | $6.32M |
| EPSd | $495K | $482.7K | $418K | $419.4K |
| Operating cash flow | $38.9M | $20.6M | $50.6M | -$-50K |
| Capital expenditure | -$-2.37M | -$-3.41M | -$-11.21M | -$-24.95M |
| Free cash flow | $36.6M | $17.2M | $39.4M | -$-24.99M |
| Total assets | $380.5M | $266.1M | $258.8M | $225.5M |
| Total debt | $51.6M | $12.2M | $22.9M | $16.1M |
| Net debt | -$-112.14M | -$-112.83M | -$-80.16M | -$-35.61M |
| Total equity | $263.3M | $195M | $143.8M | $107.9M |
| Cash and short-term investments | $164.1M | $125M | $103M | $53.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $173.6M | $205.4M | $193.5M | $174.2M |
| Cost of revenue | $46.3M | $49.4M | $56.2M | $59.3M |
| Gross profit | $127.3M | $156.1M | $137.3M | $114.8M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $58.9M | $70.1M | $66.2M | $93.5M |
| Other expenses | $940K | $15.7M | $410K | $1.23M |
| Operating expenses | $59.8M | $85.8M | $66.6M | $94.7M |
| Cost and expenses | $106.1M | $135.1M | $122.9M | $154M |
| Interest income | $200K | $20K | $90K | $470K |
| Interest expense | $160K | $30K | $50K | $30K |
| Depreciation and amortization | $2.68M | $3.8M | $12.3M | $5.93M |
| Ebitda | $84.9M | $77.3M | $85.9M | $29.6M |
| Operating income | $67.5M | $70.3M | $70.7M | $20.1M |
| Total other income/expenses, net | $14.6M | $3.15M | $2.92M | $3.56M |
| Income before tax | $82.1M | $73.5M | $73.6M | $23.7M |
| Income tax expense | $31M | $26.8M | $35M | $18.1M |
| Net income | $51M | $46.6M | $39.4M | $6.32M |
| Weighted average shares outstanding | $103M | $96.6M | $94.2M | $15.1M |
| Weighted average diluted shares outstanding | $103M | $96.6M | $94.2M | $15.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash and short-term investments | $164.1M | $125M | $103M | $53.6M |
| Net receivables | $53.1M | $48.2M | $53.1M | $43.7M |
| Inventory | $2.79M | $1.49M | $3.09M | $1.35M |
| Total current assets | $231.2M | $184.5M | $165.9M | $113M |
| Property, plant and equipment, net | $16.4M | $14M | $19.5M | $21.5M |
| Goodwill and intangible assets | $63.2M | $6.2M | $23.3M | $11.1M |
| Long-term investments | $58M | $20.9M | $20.7M | $920K |
| Total non-current assets | $149.2M | $81.6M | $92.9M | $112.5M |
| Total assets | $380.5M | $266.1M | $258.8M | $225.5M |
| Accounts payable | $17.6M | $14.5M | $26.5M | $15.3M |
| Short-term debt | $13.7M | $4.46M | $7.41M | $8.24M |
| Deferred revenue | $9.47M | $12.6M | $25.1M | $30.4M |
| Total current liabilities | $61.1M | $61.2M | $92.5M | $101.3M |
| Long-term debt | $38M | $7.75M | $15.5M | $7.89M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $56M | $9.87M | $22.5M | $16.4M |
| Capital lease obligations | $4.25M | $5.58M | $6.33M | $5.84M |
| Total liabilities | $117.1M | $71.1M | $115M | $117.6M |
| Common stock | $10K | $10K | $10K | $0.00 |
| Retained earnings | $240.5M | $189.5M | $142.9M | $103.5M |
| Accumulated other comprehensive income (loss) | -$-57.29M | -$-54.18M | -$-37.58M | -$-24.85M |
| Total equity | $263.3M | $195M | $143.8M | $107.9M |
| Total investments | $58.3M | $20.9M | $20.7M | $2.82M |
| Total debt | $51.6M | $12.2M | $22.9M | $16.1M |
| Net debt | -$-112.14M | -$-112.83M | -$-80.16M | -$-35.61M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Net income | $51M | $46.6M | $39.4M | $5.55M |
| Depreciation and amortization | $2.68M | $3.8M | $12.3M | $5.93M |
| Stock-based compensation | $0.00 | $13M | $0.00 | $0.00 |
| Change in working capital | -$-12.28M | -$-12.13M | -$-7.68M | -$-10.59M |
| Accounts receivable | $4.47M | $13.1M | -$-6.01M | -$-9.6M |
| Inventory | -$-170K | $1.12M | -$-1.83M | -$-670K |
| Accounts payable | $2.67M | -$-8.91M | $12.2M | $170K |
| Net cash provided by operating activities | $38.9M | $20.6M | $50.6M | -$-50K |
| Investments in property, plant and equipment | -$-2.79M | -$-3.41M | -$-9.52M | -$-24.95M |
| Acquisitions, net | -$-15.46M | -$-5.07M | $720K | -$-6.49M |
| Net cash used for investing activities | -$-20.97M | -$-10.1M | $1.82M | -$-32.65M |
| Common stock issued | $0.00 | $30K | $0.00 | $118.8M |
| Common stock repurchased | -$-5M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $24M | $23M | $6.14M | -$-7.98M |
| Net change in cash | $38.7M | $22M | $51.3M | -$-52.77M |
| Cash at end of period | $163.8M | $125M | $103M | $51.7M |
| Operating cash flow | $38.9M | $20.6M | $50.6M | -$-50K |
| Capital expenditure | -$-2.37M | -$-3.41M | -$-11.21M | -$-24.95M |
| Free cash flow | $36.6M | $17.2M | $39.4M | -$-24.99M |
Line items
Line items
Line items
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated provides comprehensive operational support to aesthetic and cosmetic clinics across a global footprint, including Japan, Vietnam, the United States, and other international markets. The company delivers a diverse array of administrative and support functions, such as orchestrating marketing and advertising campaigns, offering extensive human resources solutions including talent acquisition and staff training, and streamlining appointment scheduling for franchisee clinics. Furthermore, SBC Medical Group facilitates real estate arrangements for both employee housing and clinic facility rentals, oversees the design and construction of new clinics, and manages the procurement of essential medical equipment and supplies. Additionally, the firm furnishes IT software solutions. The broad spectrum of aesthetic and reconstructive procedures facilitated by SBC Medical Group's supported clinics encompasses both surgical and non-surgical interventions. These include popular treatments such as breast augmentation, liposuction, and various rejuvenation therapies targeting wrinkles, acne, scars, and signs of aging. The offerings also extend to specialized procedures like laser skin toning, double fold eye surgery, rhinoplasty, hair transplants, laser hair removal, cosmetic dental work, tattoo removal, and advanced eye procedures like LASIK, among others. Established in 2000, SBC Medical Group Holdings Incorporated maintains its headquarters in Irvine, California.
- CEO
- Yoshiyuki Aikawa
- Employees
- 863
- Beta
- 0.59
Explore
Frequently asked questions
What is the intrinsic value of SBC Medical Group Holdings Incorporated (SBC)?
SBC Medical Group Holdings Incorporated (SBC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SBC undervalued?
SBC trades at a price of $5.17 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.